(INCB).[2] The INCB reported the United States as the leading manufacturer of methylphenidate, and although the total manufacturing of methylphenidate was reported to be at the highest level since INCB began receiving data, the global stocks of methylphenidate decreased by 11 tons, from 91.6 tons in 2023 to 80.6 tons in 2024. After considering all the domestic and global data, DEA has determined that an increase to the 2026 methylphenidate (for sale) APQ is necessary to allow for the adjustment of reserve stocks to support the increasing global medical demand.

After considering the factors set forth in 21 CFR 1303.13(b) in accordance with 21 U.S.C. 826(a) as well as 826(h), DEA determined that it is necessary to increase the established 2026 APQs for the schedule II controlled substances d,l-amphetamine, d-amphetamine (for sale), hydromorphone, and methylphenidate (for sale) to be manufactured in the United States to provide for the estimated legitimate medical needs of the United States and export requirements to meet foreign demand. These adjustments are necessary to ensure that the United States has an adequate and uninterrupted supply of d,l-amphetamine, d-amphetamine (for sale), hydromorphone, and methylphenidate (for sale) to meet legitimate patient needs both domestically and globally.

Additional Legal Considerations

The procedures previously adopted by DEA for adjustment of APQ are set forth in DEA regulations in 21 CFR 1303.13. Under that provision, the Administrator, upon determining that an adjustment of the APQ of any basic class of controlled substance is necessary, shall publish in the **Federal Register** a general notice of an adjustment in the APQ for that class. The regulation further directs that DEA will allow any interested person to file comments or objections to the adjusted APQ within the time specified by the Administrator in the notice. Section 1303.13 further provides that, ''[a]fter consideration of any comments or objections . . . the Administrator shall issue and publish in the **Federal Register** his final order determining the APQ for the basic class of controlled substance.''

The statutory timeframe applicable to actions taken under 21 U.S.C. 826(h) was enacted by Congress after DEA established its regulations in 21 CFR 1303.13. DEA has determined that it is not possible to increase the APQ within the Congressionally-mandated 30-day period while also complying with the procedures that DEA previously laid out in 21 CFR 1303.13. Therefore, the Administrator has determined that, in order to comply with the 30-day timeframe in 21 U.S.C. 826(h), this final order must be published without opportunity for comment and made effective immediately.

Determination of 2026 d,l-Amphetamine, d-Amphetamine (for Sale), Hydromorphone, and Methylphenidate (for Sale) Aggregate Production Quota

In determining the adjustment of the 2026 d,l-amphetamine, d-amphetamine (for sale), hydromorphone, and methylphenidate (for sale) APQs, DEA has taken into consideration the factors set forth in 21 CFR 1303.13(b) in accordance with 21 U.S.C. 826(a) as well as 826(h). Based on all of the above, the Administrator is adjusting the 2026 APQs for d,l-amphetamine, d-amphetamine (for sale), hydromorphone, and methylphenidate (for sale).

The Administrator hereby adjusts the 2026 APQ for the following schedule II-controlled substances expressed in grams of anhydrous acid or base, as follows:

Controlled substance	Current APQ (g)	Adjusted APQ (g)
Schedule II		
d,l-amphetamine	24,234,443	31,654,915
d-amphetamine (for sale)	26,450,000	37,108,041
hydromorphone	1,949,378	2,356,798
methylphenidate (for sale)	58,283,000	69,502,651

The APQ for all other schedule I and II controlled substances included in the 2026 established APQ remain at this time as previously established.[3]

Signing Authority

This document of the Drug Enforcement Administration was signed on November 4, 2026, by DEA Administrator Terrance C. Cole. That document with the original signature and date is maintained by DEA. For administrative purposes only, and in compliance with requirements of the Office of the Federal Register, the undersigned DEA Federal Register Liaison Officer has been authorized to sign and submit the document in electronic format for publication, as an official document of DEA. This administrative process in no way alters the legal effect of this document upon publication in the **Federal Register**.

Heather Achbach,

Federal Register Liaison Officer, Drug Enforcement Administration.

[FR Doc. 2026–22842 Filed 11–9–26; 8:45 am]

BILLING CODE 4410–09–P

[2] INCB Psychotropics—Technical Report Psychotropic Substances 2025, Statistics for 2024, Assessments of Annual Medical Scientific Requirements for Substances for 2026.

[3] Established Aggregate Production Quotas for Schedule I and II Controlled Substances and Assessment of Annual Needs for the List I Chemicals Ephedrine, Pseudoephedrine, and Phenylpropanolamine for 2026, 91 FR 287 (January 5, 2026).

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

[Docket No. DEA–1730P]

Proposed Aggregate Production Quotas for Schedule I and II Controlled Substances and Assessment of Annual Needs for the List I Chemicals Ephedrine, Pseudoephedrine, and Phenylpropanolamine for 2027

AGENCY: Drug Enforcement Administration, Department of Justice.

ACTION: Notice with request for comments.

SUMMARY: The Drug Enforcement Administration (DEA) proposes to

establish the 2027 aggregate production quotas for controlled substances in schedules I and II of the Controlled Substances Act (CSA) and the assessment of annual needs for the list I chemicals ephedrine, pseudoephedrine, and phenylpropanolamine.

DATES: Interested persons may file written comments on this notice in accordance with 21 CFR 1303.11(c) and 1315.11(d). Electronic comments must be submitted, and written comments must be postmarked, on or before December 10, 2026. Commenters should be aware that the electronic Federal Docket Management System will not accept comments after 11:59 p.m. Eastern Time on the last day of the comment period.

Based on comments received in response to this notice, the Administrator may hold a public hearing on one or more issues raised. In the event the Administrator decides in his sole discretion to hold such a hearing, the Administrator will publish a notice of any such hearing in the **Federal Register**. After consideration of any comments or objections, or after a hearing, if one is held, the Administrator will publish in the **Federal Register** a final order establishing the 2027 aggregate production quotas for schedule I and II controlled substances, and an assessment of annual needs for the list I chemicals ephedrine, pseudoephedrine, and phenylpropanolamine.

ADDRESSES: To ensure proper handling of comments, please reference ''Docket No. DEA–1730P'' on all correspondence, including any attachments. DEA encourages that all comments be submitted electronically through the Federal eRulemaking Portal, which provides the ability to type short comments directly into the comment field on the web page or attach a file for lengthier comments. Please go to *www.regulations.gov* and follow the online instructions at that site for submitting comments. Upon completion of your submission, you will receive a Comment Tracking Number for your comment.

Please be aware that submitted comments are not instantaneously available for public view on *www.Regulations.gov.* If you have received a Comment Tracking Number, your comment has been successfully submitted, and there is no need to resubmit the same comment. Paper comments that duplicate electronic submissions are not necessary and are discouraged. Should you wish to mail a paper comment *in lieu* of an electronic comment, it should be sent via regular or express mail to: Drug Enforcement Administration, Attention: DEA Federal Register Representative/DPW, 8701 Morrissette Drive, Springfield, Virginia 22152.

FOR FURTHER INFORMATION CONTACT: Heather E. Achbach, Regulatory Drafting and Policy Support Section, Diversion Control Division, Drug Enforcement Administration; Mailing Address: 8701 Morrissette Drive, Springfield, Virginia 22152, Telephone: (571) 776–3882.

SUPPLEMENTARY INFORMATION:

Posting of Public Comments

Please note that all comments received in response to this docket are considered part of the public record. They will, unless reasonable cause is given, be made available by the Drug Enforcement Administration (DEA) for public inspection online at *www.regulations.gov.* Such information includes personal identifying information (such as your name, address, etc.) voluntarily submitted by the commenter.

The Freedom of Information Act applies to all comments received. If you want to submit personal identifying information (such as your name, address, etc.) as part of your comment, but do not want it to be made publicly available, you must include the phrase ''PERSONAL IDENTIFYING INFORMATION'' in the first paragraph of your comment. You must also place all the personal identifying information you do not want made publicly available in the first paragraph of your comment and identify what information you want redacted.

If you want to submit confidential business information as part of your comment, but do not want it to be made publicly available, you must include the phrase ''CONFIDENTIAL BUSINESS INFORMATION'' in the first paragraph of your comment. You must also prominently identify confidential business information to be redacted within the comment.

Comments containing personal identifying information or confidential business information identified and located as directed above will generally be made available in redacted form. If a comment contains so much confidential business information or personal identifying information that it cannot be effectively redacted, all or part of that comment may not be made publicly available. Comments posted to *www.regulations.gov* may include any personal identifying information (such as name, address, and phone number) included in the text of your electronic submission that is not identified as directed above as confidential.

An electronic copy of this document is available at *www.regulations.gov* for easy reference.

Legal Authority

Section 306 of the Controlled Substances Act (21 U.S.C. 826) requires the Attorney General to establish production quotas for each basic class of controlled substances listed in schedules I and II, and for the list I chemicals ephedrine, pseudoephedrine, and phenylpropanolamine. The Attorney General has delegated this function to the Administrator of DEA pursuant to 28 CFR 0.100.

Analysis for Proposed 2027 Aggregate Production Quotas and Assessment of Annual Needs

The proposed 2027 aggregate production quotas (APQ) and assessment of annual needs (AAN) represent those quantities of schedule I and II controlled substances, and the list I chemicals ephedrine, pseudoephedrine, and phenylpropanolamine, to be manufactured in the United States in 2027 to provide for the estimated medical, scientific, research, and industrial needs of the United States, lawful export requirements, and the establishment and maintenance of reserve stocks. These quotas include imports of ephedrine, pseudoephedrine, and phenylpropanolamine, but do not include imports of controlled substances for use in industrial processes.

Aggregate Production Quotas

In determining the proposed 2027 APQ, the Administrator has taken into account the criteria of 21 U.S.C. 826(a) and 21 CFR 1303.11, including the following seven factors:

(1) Total net disposal of the class by all manufacturers during the current and two preceding years;

(2) Trends in the national rate of net disposal of the class;

(3) Total actual (or estimated) inventories of the class and of all substances manufactured from the class, and trends in inventory accumulation;

(4) Projected demand for such class as indicated by procurement quotas requested pursuant to [21 CFR] 1303.12;

(5) The extent of any diversion of the controlled substance in the class;

(6) Relevant information obtained from the Department of Health and Human Services (HHS), including from the Food and Drug Administration (FDA), the Centers for Disease Control

and Prevention (CDC), and the Centers for Medicare and Medicaid Services (CMS), and relevant information obtained from the states; and

(7) Other factors affecting medical, scientific, research, and industrial needs in the United States and lawful export requirements, as the Administrator finds relevant, including changes in the currently accepted medical use in treatment with the class or the substances manufactured from it, the economic and physical availability of raw materials for use in manufacturing and for inventory purposes, yield and stability problems, potential disruptions to production (including possible labor strikes), and recent unforeseen emergencies such as floods and fires. 21 CFR 1303.11(b).

DEA formally solicited data from FDA and CDC in March of 2026 and from the states in April 2026, pursuant to 21 CFR part 1303. DEA did not solicit input from CMS for reasons discussed in previous notices.[1] DEA requested information on trends in the legitimate use of select schedule I and II controlled substances from FDA and rates of overdose deaths for covered controlled substances from CDC. DEA's request for information from the states was made directly to the Prescription Drug Monitoring Program (PDMP) Administrators in each state as well as through the National Association of State Controlled Substances Authorities (NASCSA).

Assessment of Annual Needs

In similar fashion, in determining the proposed 2027 AAN for the list I chemicals ephedrine, pseudoephedrine, and phenylpropanolamine, the Administrator has taken into account the criteria of 21 U.S.C. 826(a) and 21 CFR 1315.11, including the following five factors:

(1) Total net disposal of the chemical by all manufacturers and importers during the current and two preceding years;

(2) Trends in the national rate of net disposal of each chemical;

(3) Total actual (or estimated) inventories of the chemical and of all substances manufactured from the chemical, and trends in inventory accumulation;

(4) Projected demand for each chemical as indicated by procurement and import quotas requested pursuant to [21 CFR] 1315.32; and

(5) Other factors affecting medical, scientific, research, and industrial needs in the United States, lawful export requirements, and the establishment and maintenance of reserve stocks, as the Administrator finds relevant, including changes in the currently accepted medical use in treatment with the chemicals or the substances manufactured from them, the economic and physical availability of raw materials for use in manufacturing and for inventory purposes, yield and stability problems, potential disruptions to production (including possible labor strikes), and recent unforeseen emergencies such as floods and fires. 21 CFR 1315.11(b).

In determining the proposed 2027 AAN, DEA used the calculation methodology previously described in the 2010 and 2011 assessments of annual needs (74 FR 60294 (Nov. 20, 2009) and 75 FR 79407 (Dec. 20, 2010), respectively).

Projected Trends for Certain Schedule II Controlled Substances

In accordance with 21 CFR part 1303, 21 U.S.C. 826, and 42 U.S.C. 242, HHS continues to provide DEA with estimates of the quantities of select schedule I and II controlled substances and three list I chemicals that will be required to meet the legitimate medical needs of the United States for a given calendar year. The responsibility to provide these estimates of legitimate domestic medical needs resides with FDA. FDA provides DEA with predicted estimates of domestic medical usage for selected controlled substances based on information available to them at a specific point in time in order to meet statutory requirements. In July 2026, FDA provided DEA with the predicted estimates of domestic medical usage for selected controlled substances for 2027, which DEA considered in developing the proposed 2027 APQ.

FDA predicts that levels of medical usage for schedule II opioids in the United States in calendar year 2027 will decline on average 9.68 percent from calendar year 2026 levels. These declines are expected to occur across a variety of schedule II opioids including fentanyl, hydrocodone, hydromorphone, oxycodone, and oxymorphone. DEA considered the potential for diversion of schedule II opioids, as required by 21 CFR 1303.11(b)(5), in developing the proposed 2027 APQ. Accordingly, the APQs for fentanyl, hydrocodone (for sale), hydromorphone, oxycodone (for sale), and oxymorphone (for sale) are being proposed as reductions from their 2026 proposed revised APQ values.

FDA also provided a predicted 3.93 percent increase on average of domestic medical use of schedule II stimulants in calendar year 2027, including d-amphetamine (for sale), d,l-amphetamine, lisdexamfetamine, and methylphenidate, which are prescribed to treat patients with attention deficit hyperactivity disorder (ADHD), from calendar year 2026 levels. FDA also raised concerns over drug shortages potentially related to the growth in telemedicine, supply chain issues, manufacturing and quality issues, and business decisions of manufacturers, which DEA considered in developing the proposed 2027 APQ. DEA recently proposed to increase the 2026 APQs for both lisdexamfetamine and methylphenidate (for sale) and is proposing the same increased values for 2027 in part to address these concerns.

DEA is proposing the 2027 APQs for the schedule II stimulants d,l-amphetamine and d-amphetamine (for sale) at higher levels than their 2026 proposed revised APQ values to address the growth in prescribing, export requirements, the global market, and to ensure sufficient inventory for domestic manufacturers of FDA-approved drug products. Medications containing one or both of these controlled substances are commonly prescribed to treat patients with ADHD. Over the past few years, dosage form manufacturers have been intermittently reporting shortages of specific ADHD medications containing amphetamine to FDA. The stated reasons for these specific shortages include increases in product demand, supply chain issues, manufacturing and quality issues, lack of active ingredients, and business decisions of manufacturers. FDA estimated a 3.90 percent increase in domestic medical usage individually for d-amphetamine (for sale) and d,l- amphetamine. DEA reviewed the most recently available domestic usage data from IQVIA and export data from DEA's internal database and Multi International Data Analysis System (MIDAS). The projection from this data estimated use for d-amphetamine (for sale) and d,l-amphetamine each increased by 6.98 percent. DEA also considered the manufacturers' reported inventories for amphetamine-based products and their drug shortage concerns when determining the proposed APQs for these substances. DEA believes the inventories, when combined with the proposed 2027 APQs, will be sufficient to support the estimated increases in

[1] Proposed Adjustments to the Aggregate Production Quotas for Schedule I and II Controlled Substances and Assessment of Annual Needs for List I Chemicals Ephedrine, Pseudoephedrine, and Phenylpropanolamine for 2020, 85 FR 54414 (Sept. 1, 2020) and Proposed Aggregate Production Quotas for Schedule I and II Controlled Substances and Assessment of Annual Needs for List I Chemicals Ephedrine, Pseudoephedrine, and Phenylpropanolamine for 2021, 85 FR 54407 (Sept. 1, 2020).

domestic medical use and export requirements of amphetamine products.

DEA is proposing the pentobarbital APQ at a higher level than the 2026 established APQ to support *Executive Order 14336:* Ensuring American Pharmaceutical Supply Chain Resilience by Filling the Strategic Active Pharmaceutical Ingredients Reserve. The 2027 proposed pentobarbital increase is greater than the 2026 proposed revised APQ to allow for a reserve stockpile of the API for manufacturing established essential medications containing pentobarbital based on the request from Administration for Strategic Preparedness and Response (ASPR).

DEA Projected Trends for Certain Schedule I Controlled Substances

On August 12, 2026, DEA published in the **Federal Register** a temporary scheduling order to place O-desmethyltramadol in schedule I of the CSA until August 12, 2028, or until a permanent schedule action of this substance is complete, whichever occurs first.[2] Therefore, DEA is proposing an APQ for this basic class for the first time. DEA is also proposing the 2027 APQs for acetyl fentanyl and heroin at lower levels than their 2026 proposed revised APQ based on the decline in the amount of quota requested to support medical, scientific, research, and industrial needs. These decreases in the APQs will not affect the ability of these manufacturers to meet the estimated medical, scientific, research, and industrial needs of the U.S., lawful export requirements, and the establishment and maintenance of reserve stocks.

DEA is proposing higher APQs than the 2026 proposed revised APQs for the following schedule I controlled substances: 3,4-Methylenedioxymethamphetamine (MDMA) and ibogaine to support manufacturing activities related to the increased level of research and clinical trials being conducted with these substances for potential treatment of conditions including post-traumatic stress disorder (PTSD) and depression. This increase in research and clinical trials aligns with two Presidential Executive Orders (E.O.). First, *E.O. 14379:* Addressing Addiction through the Great American Recovery Initiative,[3] which prioritizes addiction treatment and recovery. Second, *E.O. 14401:* Accelerating Medical Treatments for Serious Mental Illness,[4] which requires a pathway to be established for eligible patients to access psychedelic drugs, including ibogaine compounds, under the Right to Try Act (21 U.S.C. 360bbb–0a). Additionally, DEA is proposing a lower APQ than the 2026 proposed revised APQ for fentanyl-related substances based on the diminished needs of manufacturers who produce reference standards or support research.

Information Received for Consideration of the Remaining Factors

For the factors listed in 21 CFR 1303.11(b)(3) and (4), DEA registered manufacturers of controlled substances in schedules I and II provide information such as inventory, distribution, manufacturing, sales forecasts and quota requests to DEA database systems. *See,* 21 CFR 1303.12, 1303.22, and part 1304.

The regulation at 21 CFR 1303.11(b)(5) requires DEA to consider the extent of diversion of controlled substances.[5] Diversion is defined as all distribution, dispensing, or other use of controlled substances for other than legitimate medical purposes. In considering the extent of diversion, DEA analyzed reports of diversion of controlled substances from 2025 submitted to its Theft Loss Report database. This database is comprised of DEA registrant reports documenting diversion from the legitimate distribution chain, including employee thefts, break-ins, armed robberies, and material lost in transit. The data was categorized by basic drug class, and the amount of Active Pharmaceutical Ingredient (API) in the dosage form was delineated with an appropriate metric for use in proposing aggregate production quota values (*i.e.,* weight).

Estimates of Diversion of Covered Controlled Substances

In establishing any quota . . . , or any procurement quota established by [DEA] by regulation, for fentanyl, oxycodone, hydrocodone, oxymorphone, or hydromorphone (in this subsection referred to as a ''covered controlled substance''), [DEA] shall estimate the amount of diversion of the covered controlled substance that occurs in the United States.

21 U.S.C. 826(i)(1)(A).

In estimating diversion under that provision, DEA:

(i) shall consider information . . . , in consultation with the Secretary of Health and Human Services, [it] determines reliable on rates of overdose deaths and abuse and overall public health impact related to the covered controlled substance in the United States; and

(ii) may take into consideration whatever other sources of information [it] determines reliable.

21 U.S.C. 826(i)(1)(B).

The statute further mandates that DEA ''make appropriate quota reductions, as determined by [DEA], from the quota [it] would have otherwise established had such diversion not been considered.'' [6]

In estimating the amount of diversion of each covered controlled substance that occurs in the United States, DEA considered information from state PDMP Administrators and from legitimate distribution chain participants.

Consideration of Information From Certain State PDMPs and From National Sales Data

Pursuant to 21 CFR 1303.11(b)(6), DEA requested state PDMP data for the purpose of establishing its APQ. DEA believes state PDMPs to be an essential, reliable source of information for use in effectively estimating diversion of the five covered controlled substances. In April 2026, DEA sent a letter to NASCSA requesting its assistance in obtaining aggregated PDMP data for the five covered controlled substances from each state covering the years 2022–2025. The letter indicated that DEA was specifically interested in an analysis of prescription data from each state's PDMP that would assist DEA in estimating diversion and setting appropriate quotas in compliance with 21 U.S.C. 826(i). In its request, DEA provided specific questions, discussed in detail below, based on common indicia of potential diversion known as ''red flags'' by physicians, pharmacists, manufacturers, distributors, and federal and state regulatory and law enforcement agencies.[7] DEA investigators and administrative prosecutors also rely on Agency case law in which these red flags of diversion have been upheld as indicia of potential diversion.[8] Certain state regulations

[2] 91 FR 52013 (August 12, 2026).

[3] Addressing Addiction Through the Great American Recovery Initiative, Executive Order 14379 of January 29, 2026.

[4] Accelerating Medical Treatments for Serious Mental Illness, Executive Order 14401 of April 18, 2026.

[5] The estimates of diversion for five ''covered controlled substances'' as required by 21 U.S.C. 826(i) are discussed later in the document.

[6] 21 U.S.C. 826(i)(1)(C).

[7] National Association of Boards of Pharmacy (NABP) coalition consensus document ''Stakeholders' Challenges and Red Flag Warning Signs Related to Prescribing and Dispensing Controlled Substances'' (2015). www.nabp.pharmacy/resources/reports.

[8] The Medicine Shoppe, 79 FR 59504, 59507, 59512–13 (Oct. 2, 2014); Holiday CVS, L.L.C., d/b/

Continued

now include red flag circumstances as potential indicators of illegitimate prescriptions, and thus of potential abuse and diversion of controlled substances.[9] *See, e.g.,* The Pharmacy Place Order, 86 FR 21008, 21012 (Apr. 21, 2021) (citing 22 Tex. Admin. Code 291.29(c)(4), specifying the geographical distance between the practitioner and the patient or between the pharmacy and the patient as a red flag).

DEA requested responses from state PDMP Administrators by June 15, 2026. NASCSA disseminated DEA's request to its PDMP Administrators and provided them with a report tool to ensure that responses to DEA's questions were extracted consistently across all responsive states. Thirty-six states and two territories provided DEA with summarized PDMP data as of July 2026, utilizing the standardized report developed by NASCSA.[10] *See,* Table 1a below.

TABLE 1a—STATES/TERRITORIES THAT RESPONDED TO DEA'S DATA REQUEST

State/territory
1. Alabama
2. Alaska
3. Arkansas
4. Connecticut
5. Delaware
6. Florida
7. Idaho
8. Illinois
9. Indiana
10. Iowa
11. Kansas
12. Louisiana
13. Maine
14. Maryland
15. Massachusetts
16. Michigan
17. Minnesota
18. Mississippi
19. Missouri
20. Montana
21. Nevada
22. New Jersey
23. New Mexico
24. New York
25. North Carolina
26. North Dakota
27. Ohio
28. Oklahoma
29. Oregon
30. Pennsylvania
31. South Carolina
32. South Dakota
33. Texas
34. Utah
35. Vermont
36. Virginia
37. Puerto Rico
38. Northern Mariana Islands

Pharmacies are required by state law to enter controlled substance dispensing data into the state's PDMP database, including the prescriber's name, registered address and DEA number; prescription information (such as drug name); dispensing date; dosage dispensed; pharmacy registered address; and patient name and address. DEA considers PDMP data to be an accurate representation of dispensing activities in states. DEA received data for the following red-flag metrics:

- The total number of patients who saw three or more prescribers in a 90-day period and were dispensed an opioid following each visit. For this metric, DEA requested and was provided the number of prescriptions for the five covered controlled substances dispensed to these patients, as a percentage of the total prescriptions dispensed for that particular covered controlled substance, as well as the corresponding quantity of the covered controlled substance dispensed. This metric (patients being prescribed covered controlled substances from three or more prescribers in a 90-day period) is used to identify potential doctor shopping, a common technique to obtain a high number of controlled substances, which may lead to abuse or diversion of controlled substances. DEA has long considered doctor shopping to be an indicator of potential diversion.[11]
- The number of patients that were dispensed prescriptions for each of the five covered controlled substances that exceeded 240 morphine milligram equivalents (MME) daily. States provided the raw number of such prescriptions dispensed, the number of prescriptions as a percentage of the total covered controlled substance prescriptions dispensed, and the corresponding quantity of the covered controlled substance dispensed. DEA believes that accounting for quantities in excess of 240 MME daily allows for consideration of oncology patients with legitimate medical needs for covered controlled substance prescriptions with high MME. Higher dosages place individuals at higher risk of overdose and death. Prescriptions involving dosages exceeding 240 MME daily may indicate diversion, such as illegal distribution of controlled substances or prescribing outside the usual course of professional practice.
- The number of patients that paid cash for covered controlled substance prescriptions, without submitting for insurance reimbursement.[12] States also provided the number of prescriptions paid entirely with cash as a percentage of the total prescriptions for the five covered controlled substances dispensed, as well as the corresponding quantity of the covered controlled substances dispensed. When investigating potential diversion, cash payments are one element considered in identifying prescriptions filled for nonmedical purposes. Unusually high percentages of cash payments made to a prescriber or pharmacy for controlled substances may indicate diversion.[13]

DEA received PDMP data from the states in a standardized format that allowed DEA to aggregate the data. The PDMP data sample represents a population of approximately 213.76 million people, which is approximately 62 percent of the U.S. population. DEA believes this sample is sufficient to derive a reasonable nationwide estimate.

While PDMP data is useful in estimating diversion, it is not conclusive. Further investigation would be required before concluding that any of the subject prescriptions were actually diverted. DEA continues to evaluate its methodologies in estimating diversion in an effort to set quotas more efficiently. State participation is crucial to accurate data analysis, and DEA anticipates working closely with states, as well as other federal and state entities, in future quota determinations.

To calculate a national diversion estimate for each of the covered controlled substances from the responses received from state PDMP Administrators, DEA relied upon the number of individuals who received a prescription for a covered controlled substance that met any of the three red-flag metrics for each of calendar years 2022–2025. Using the population of the states responding to DEA's request, DEA

a CVS Pharmacy Nos. 219 and 5195, 77 FR 62316 (Oct. 12, 2012).

[9] The mere indicia of red flags alone is not proof of violation of 21 U.S.C. 824 or any other provision of the CSA. This rule discusses only their use by DEA as an analytical tool to estimate diversion.

[10] NASCSA formatted DEA's request into an analytics model developed by one of its associates, Appriss Inc.

[11] Frank's Corner Pharmacy, 60 FR 17574 (Apr. 6, 1995); Holiday CVS, L.L.C., d/b/a CVS Pharmacy Nos. 219 and 5195, 77 FR 62316 (Oct. 12, 2012).

[12] This total does not include insurance co-payments made with cash.

[13] Suntree Pharmacy and Suntree Medical Equipment, LLC, 85 FR 73753 (Nov. 19, 2020) (finding that the pharmacy filled prescriptions despite the presence of multiple unresolved red flags, including cash payments); Pharmacy Doctors Enterprises d/b/a Zion Clinic Pharmacy, 83 FR 10876 (Mar. 13, 2018) (revoking pharmacy's registration for filling prescriptions that raised the red flag of customers paying cash for their prescriptions, among other red flags).

then calculated the percentage of the population issued a prescription with a red flag. Using this estimated percentage for 2022–2025, DEA analyzed trends in the data to predict the estimated percentage of patients who would be expected to be included in these red-flag metrics for 2027.

DEA also reviewed aggregate sales data for each of the covered controlled substances, which it extracted from IQVIA's National Sales Perspective.[14] IQVIA sales data was selected to help quantify diversion at the national level because it reflects the best national estimate for all prescriptions written and filled, including the total quantity available for diversion or misuse. To predict the estimated national sales for 2027, DEA analyzed trends in IQVIA sales data from January 2021–April 2026.

To estimate diversion for each of the covered controlled substances, DEA multiplied the forecasted percentage of patients likely to receive a prescription for a covered controlled substance that meet any of the three red-flag metrics in 2027 by the forecasted sales data from IQVIA for 2027. The resulting estimate of diversion from data submitted by state PDMP Administrators is summarized below in Table 1b. This data contributed to the final diversion estimate set forth in Table 3.

TABLE 1b—DIVERSION ESTIMATES FOR 2027 BASED ON STATE PDMP DATA FOR COVERED CONTROLLED SUBSTANCES FOR 2025

Controlled substance	(g)
Fentanyl	46
Hydrocodone	126,636
Hydromorphone	595
Oxycodone	380,276
Oxymorphone	0

Consideration of Registrant Reported Diversion in the Legitimate Distribution Chain

DEA extracted data from its Theft Loss Report database and categorized it by each basic drug class. DEA calculated the estimated amount of diversion by multiplying the quantity of API in each finished dosage form by the total amount of units reported stolen or lost to estimate the metric weight in grams of the controlled substance being diverted. This estimate of diversion from the legitimate supply chain for each of the covered controlled substances is displayed in Table 2. This data contributed to the final diversion estimates set forth in Table 3.

TABLE 2—DIVERSION ESTIMATES BASED ON SUPPLY CHAIN DIVERSION DATA FOR COVERED CONTROLLED SUBSTANCES

Controlled substance	(g)
Fentanyl	162
Hydrocodone	9,213
Hydromorphone	582
Oxycodone	27,441
Oxymorphone	97

In accordance with 21 U.S.C. 826(i), DEA's estimate of diversion for the five controlled substances was calculated by combining the values in Tables 1b and 2.

TABLE 3—TOTAL ESTIMATES OF DIVERSION FOR COVERED CONTROLLED SUBSTANCES TO BE CONSIDERED IN THE 2027 APQS

Controlled substance	(g)
Fentanyl	208
Hydrocodone	135,849
Hydromorphone	1,177
Oxycodone	407,717
Oxymorphone	97

Continuing Efforts to Anticipate and Prevent Drug Shortages

DEA remains committed to monitoring drug shortages, limiting their impact, and resolving them as quickly as possible. DEA continues to seek additional information that will assist in accurately forecasting domestic medical usage and export requirements of schedule I or II substances. As documented in the 2026 established APQ **Federal Register** notice DEA began utilizing IQVIA's foreign (non-U.S.) sales tracking data module in February 2024, MIDAS, which provides valuable insight into the growing export markets for schedule II stimulants. In March 2025, DEA sent a letter requesting DEA-registered manufacturers and distributors to voluntarily switch their DEA ARCOS database reporting from a quarterly to monthly basis. As of July 14, 2026, 47% of all ARCOS reporting DEA-registered manufacturers, distributors and reverse distributors report to ARCOS monthly. DEA remains committed to ensuring that all patients with legitimate medical need can access appropriately prescribed medications.

Quota Requirements for Controlled Substances in Schedule III of the Controlled Substances Act

On April 28, 2026, the Acting Attorney General issued *Schedules of Controlled Substances: Rescheduling of Food and Drug Administration Approved Products Containing Marijuana From Schedule I to Schedule III; Corresponding Change to Permit Requirements* as a final rule which became effective on April 28, 2026.[15] This final rule places in schedule III drug products containing marijuana that have been approved by the FDA and drug products subject to a state medical marijuana license. The final rule assigned separate drug codes for schedule III marijuana in an FDA-approved product or subject to a state medical marijuana license, schedule III marijuana extract in an FDA-approved product or subject to a state medical marijuana license, and schedule III naturally-derived delta-9-tetrahydrocannabinols in an FDA-approved product or subject to a state medical marijuana license (drug codes 7362, 7353, 7386).

The final rule outlines several control measures required to satisfy the United States obligations under the Single Convention on Narcotic Drugs, 1961, as well as the CSA. Two related control measures of the Single Convention require: (1) manufacturers and distributors of drugs listed in Schedule I of the Convention, including marijuana, to be licensed (Articles 29 & 30); and (2) licensed manufacturers of drugs listed in Schedule I of the Convention obtain quotas specifying the amounts of such drugs they may manufacture to prevent excessive production and accumulation beyond that necessary to satisfy legitimate needs. (Articles 21 & 29). DEA is currently in the process of registering the manufacturers and distributors who will be handling the substances that have been moved to schedule III under the CSA as outlined in the final rule. Concurrently, DEA is assessing data sources and methodologies to determine the most reliable and relevant datasets for the estimation of the United States' legitimate need and production requirements for these 3 substances. Therefore, the APQ table below continues to reflect the APQs for the schedule I marijuana, marijuana extract, and delta-9-tetrahydrocananbinol (drug codes 7360, 7350, 7370) only. A separate notice will be published in the **Federal Register** once the proposed APQs for the schedule III substances

[14] DEA has purchased this data from IQVIA for decades and routinely uses this information to administer several regulatory functions, including the administration of DEA's quota program.

[15] 91 FR 22714 (April 28, 2026).

(drug codes 7362, 7353, 7386) are determined.

The Administrator, therefore, proposes to establish the 2027 APQ for certain schedule I and II controlled substances and AAN for the list I chemicals ephedrine, pseudoephedrine, and phenylpropanolamine, expressed in grams of anhydrous acid or base, as follows:

Basic class	Established 2027 quotas (g)
Temporary Schedule I	
2-Fluorodeschloroketamine	30
5-Methyl Etodesnitazene	30
Bromazolam	30
Ethyleneoxynitazene	30
Methylenedioxynitazene	30
N,N-Dimethylamino Etonitazene	30
N-Desethyl Etonitazene	30
N-Desethyl Protonitazene	30
N-Pyrrolidino Isotonitazene	30
O-Desmethyltramadol	30
Schedule I	
1-[1-(2-Thienyl)cyclohexyl]pyrrolidine	20
1-(1-Phenylcyclohexyl)pyrrolidine	30
1-(2-Phenylethyl)-4-phenyl-4-acetoxypiperidine	10
1-(4-Methoxyphenyl)-N-methylpropan-2-amine (Para-methoxymethamphetamine)	30
1-(5-Fluoropentyl)-3-(1-naphthoyl) indole (AM2201)	30
1-Benzylpiperazine	25
1-Methyl-4-phenyl-4-propionoxypiperidine	10
1-[1-(2-Thienyl)cyclohexyl]piperidine	15
2'-Fluoro 2-fluorofentanyl	30
2,5-Dimethoxy-4-Ethylamphetamine (DOET)	25
2,5-Dimethoxy-4-(n)-Propylthiophenethylamine	25
2,5-Dimethoxyamphetamine	25
2-(2,5-Dimethoxy-4-(n)-propylphenyl)ethanamine (2C–P)	30
2-(2,5-Dimethoxy-4-ethylphenyl)ethanamine (2C–E)	30
2-(2,5-Dimethoxy-4-methylphenyl)ethanamine (2C–D)	30
2-(2,5-Dimethoxy-4-nitro-phenyl)ethanamine (2C–N)	30
2-(2,5-Dimethoxyphenyl)ethanamine (2C–H)	100
2-(4-Bromo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25B–NBOMe; 2C–B–NBOMe; 25B; Cimbi-36)	30
2-(4-Chloro-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25C–NBOMe; 2C–C–NBOMe; 25C; Cimbi-82)	25
2-(4-Chloro-2,5-dimethoxyphenyl)ethanamine (2C–C)	30
2-(4-Ethoxybenzyl)-5-Nitro-1-(2-(Piperidin-1-yl)Ethyl)-1H-Benzimidazole (N-Piperidinyl Etonitazene)	30
2-(4-Iodo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25I–NBOMe; 2C–I–NBOMe; 25I; Cimbi-5)	30
2-(4-Iodo-2,5-dimethoxyphenyl)ethanamine (2C–I)	30
2-(Ethylamino)-2-(3-Methoxyphenyl)Cyclohexan-1-One (Methoxetamine)	30
2-Methyl AP–237	30
2-[4-(Ethylthio)-2,5-dimethoxyphenyl]ethanamine (2C–T–2)	30
2-[4-(Isopropylthio)-2,5-dimethoxyphenyl]ethanamine (2C–T–4)	30
3,4,5-Trimethoxyamphetamine	30
3,4-Methylenedioxyamphetamine (MDA)	12,000
3,4-Methylenedioxy-N-ethylamphetamine (MDEA)	40
3,4-Methylenedioxy-N-methylcathinone (methylone)	42,500
3,4-Methylenedioxymethamphetamine (MDMA)	33,296
3,4-Methylenedioxypyrovalerone (MDPV)	35
3–FMC; 3-Fluoro-N-methylcathinone	25
3-Methoxyphencyclidine (1-(1-(3-Methoxyphenyl)cyclohexyl)piperidine)	30
3-Methylfentanyl	30
3-Methylthiofentanyl	30
3-Methylmethcathinone	30
4′-Methyl acetyl fentanyl	30
4'-Methyl-alpha-pyrrolidinohexiophenone (MPHP)	25
4,4′-Dimethylaminorex	30
4-Bromo-2,5-dimethoxyamphetamine (DOB)	30
4-Bromo-2,5-dimethoxyphenethylamine (2–CB)	5,100
4-Chloro-alpha-pyrrolidinovalerophenone (4-chloro-alpha-PVP)	25
4-Chloromethcathinone	30
4–CN-Cumyl-Butinaca	25
4-Fluoroamphetamine	30
4-Fluoroisobutyryl fentanyl	30
4–FMC; Flephedrone	25
4–MEC; 4-Methyl-N-ethylcathinone	25
4-Methoxyamphetamine	150

Basic class	Established 2027 quotas (g)
4-Methyl-2,5-dimethoxyamphetamine (DOM)	25
4-Methyl-alpha-ethylaminopentiophenone (4–MEAP)	25
4-Methyl-alpha-pyrrolidinopropiophenone (4-MePPP)	25
4-Methyl-N-methylcathinone (mephedrone)	45
4-Methylaminorex	25
4F–MDMB–BUTICA	30
5-Fluoro-PB–22; 5F–PB–22	25
5-Fluoro-UR144, XLR11 ([1-(5-fluoro-pentyl)-1Hindol-3-yl](2,2,3,3-tetramethylcyclopropyl)methanone	25
5-Methoxy-3,4-methylenedioxyamphetamine	25
5-Methoxy-N,N-diisopropyltryptamine	25
5-Methoxy-N,N-dimethyltryptamine	30,000
5F–AB–PINACA ; (1-Amino-3-methyl-1-oxobutan-2-yl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide	25
5F–ADB; 5F–MDMB–PINACA (methyl 2-(1-(5-fluoropentyl)-1H-indazole-3-carboxamido)-3,3-dimethylbutanoate)	25
5F–AMB (methyl 2-(1-(5-fluoropentyl)-1H-indazole-3-carboxamido)-3-methylbutanoate)	25
5F–APINACA; 5F–AKB48 (N-(adamantan-1-yl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide)	25
5F–CUMYL–P7AICA; 1-(5-Fluoropentyl)-N-(2-phenylpropan-2-yl)-1H-pyrrolo[2,3-b]pyridine-3carboximide	25
5F–CUMYL–PINACA	25
5F–EDMB–PICA	30
5F–EDMB–PINACA	25
5F–MDMB–PICA	25
A–PIHP; 4-methyl-1-phenyl-2-(pyrrolidin-1-yl)pentan-1-one (alpha-PiHP)	30
AB–CHMINACA	30
AB–FUBINACA	50
AB–PINACA	30
Acetorphine	25
Acetyl Fentanyl	30
Acetyl-alpha-methylfentanyl	30
Acetyldihydrocodeine	30
Acetylmethadol	25
Acryl Fentanyl	25
ADB–4en–PINACA	30
ADB–BUTINACA	30
ADB–FUBINACA (N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide)	30
ADB–PINACA (N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide)	50
AH–7921	30
All other tetrahydrocannabinol	1,166,130
Allylprodine	25
alpha-Ethyltryptamine	25
alpha-Methylfentanyl	30
alpha-Methylthiofentanyl	30
alpha-Methyltryptamine (AMT)	25
alpha-Pyrrolidinobutiophenone (α-PBP)	25
alpha-pyrrolidinoheptaphenone (PV8)	25
alpha-pyrrolidinohexabophenone (alpha-PHP)	25
alpha-Pyrrolidinopentiophenone (α-PVP)	25
Alphacetylmethadol	25
Alphameprodine	25
Alphamethadol	25
Amineptine	30
Aminorex	25
Anileridine	20
APINCA, AKB48 (N-(1-adamantyl)-1-pentyl-1H-indazole-3-carboxamide)	25
Benzethidine	25
Benzylmorphine	30
beta-Hydroxy-3-methylfentanyl	30
beta-Hydroxyfentanyl	30
beta-Hydroxythiofentanyl	30
beta-Methyl fentanyl	30
beta-Methylacetyl fentanyl	30
beta′-Phenyl fentanyl	30
Betacetylmethadol	25
Betameprodine	25
Betamethadol	25
Betaprodine	25
Brorphine	30
Bufotenine	15
Butonitazene	30
Butylone	25
Butyryl fentanyl	30
Cathinone	40
Cannabimimetic Agents	620

Basic class	Established 2027 quotas (g)
Clonazolam	30
Clonitazene	25
Codeine methylbromide	30
Codeine-N-oxide	192
Crotonyl Fentanyl	25
CUMYL–PEGACLONE	30
Cyclopentyl Fentanyl	30
Cyclopropyl Fentanyl	20
Cyprenorphine	25
delta-9-Tetrahydrocannabinol	1,523,040
Desomorphine	25
Dextromoramide	25
Diapromide	20
Diclazepam	30
Diethylthiambutene	20
Diethyltryptamine	25
Difenoxin	9,300
Dihydromorphine	639,954
Dimenoxadol	25
Dimepheptanol	25
Dimethylthiambutene	20
Dimethyltryptamine	25,000
Dioxyaphetyl butyrate	25
Dipentylone	30
Dipipanone	25
Drotebanol	25
Ethylmethylthiambutene	25
Ethylone	25
Ethylphenidate	30
Etizolam	30
Etodesnitazene	30
Etonitazene	25
Etorphine	30
Etoxeridine	25
Eutylone	30
Fenethylline	30
Fentanyl carbamate	30
Fentanyl related substances	300
Flualprazolam	30
Flubromazolam	30
Flunitazene	30
FUB–144	25
FUB–AKB48	25
FUB–AMB, MMB-Fubinaca, AMB-Fubinaca	25
Furanyl fentanyl	30
Furethidine	25
gamma-Hydroxybutyric acid	49,675,266
Heroin	100
Hexahydrocannabinol	30
Hydromorphinol	40
Hydroxypethidine	25
Ibogaine	12,002
Isobutyryl Fentanyl	25
Isotonitazine	25
JWH–018 and AM678 (1-Pentyl-3-(1-naphthoyl)indole)	35
Ketobemidone	30
Levomoramide	25
Levophenyacylmorphan	25
Lysergic acid diethylamide (LSD)	1,200
MAB–CHMINACA; ADB–CHMINACA (N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide)	30
Marijuana	6,675,000
Marijuana extract	1,000,000
MDMB–4EN–PINACA	30
MDMB–CHMICA; MMB–CHMINACA(methyl 2-(1-(cyclohexylmethyl)-1H-indole-3-carboxamido)-3,3-dimethylbutanoate)	30
MDMB–FUBINACA (methyl 2-(1-(4-fluorobenzyl)-1H-indazole-3-carboxamido)-3,3-dimethylbutanoate)	30
Mecloqualone	30
Mescaline	1,200
Mesocarb	30
meta-Fluorofuranyl fentanyl	30
Methaqualone	60

Basic class	Established 2027 quotas (g)
Methcathinone	25
Methiopropamine	30
Methoxyacetyl fentanyl	30
Methyl 2-(1-(4-fluorobutyl)-1H-indazole-3-carboxamido)-3,3-dimethylbutanoate (4F–MDMB–BINACA)	30
Methyldesorphine	5
Methyldihydromorphine	25
Metodesnitazene	30
Metonitazene	30
MMB–CHMICA; (AMB–CHIMCA); Methyl-2-(1-(cyclohexylmethyl)-1H-indole-3-carboxamido)-3-methylbutanoate	25
MMB–FUBICA	30
Morpheridine	25
Morphine methylbromide	5
Morphine methylsulfonate	5
Morphine-N-oxide	150
MT–45	30
Myrophine	25
N,N-Dimethylamphetamine	25
N-Ethyl-1-phenylcyclohexylamine	25
N-Desethyl Isotonitazene (N-Ethyl-2-(2-(4-isopropoxybenzyl)-5-nitro-1H- benzimidazol-1-yl)ethan-1-amine)	30
N-Ethyl-3-piperidyl benzilate	10
N-Ethylamphetamine	24
N-Ethylhexedrone	25
N-Ethylpentylone, ephylone	30
N-Hydroxy-3,4-methylenedioxyamphetamine	24
N-Methyl-3-piperidyl benzilate	30
N-Pyrrolidino Etonitazene	30
N-pyrrolidino metonitazene	30
N-pyrrolidino protonitazene	30
Naphyrone	25
Nicocodeine	25
Nicomorphine	25
NM2201: Naphthalen-1-yl 1-(5-fluorpentyl)-1H-indole-3-carboxylate	25
Noracymethadol	25
Norlevorphanol	2,550
Normethadone	25
Normorphine	40
Norpipanone	25
Ocfentanil	25
ortho-Chlorofentanyl	30
ortho-Fluoroacryl fentanyl	30
ortho-Fluorobutyryl fentanyl	30
ortho-Fluorofentanyl,2-Fluorofentanyl	30
ortho-Fluoroisobutyryl fentanyl	30
ortho-Methyl acetylfentanyl	30
ortho -Methylcyclopropylfentanyll	30
ortho-Methyl methoxyacetyl fentanyl	30
para-Chlorofentanyl	30
para-Chloroisobutyrl fentanyl	30
para-Flourobutyryl fentanyl	25
para-Fluorofentanyl	25
para-Fluoro furanyl fentanyl	30
para-Fluoro valeryl fentanyl	30
para-Methoxybutyrl fentanyl	30
para-Methylfentanyl	30
Parahexyl	5
PB–22; QUPIC	20
Pentedrone	25
Pentylone	25
Phenadoxone	25
Phenampromide	25
Phenomorphan	25
Phenoperidine	25
Phenyl fentanyl	30
Pholcodine	5
Piritramide	25
Proheptazine	25
Properidine	25
Propiram	25
Protonitazene	30
Psilocybin	60,000
Psilocyn	93,600

Basic class	Established 2027 quotas (g)
Racemoramide	25
Tetrahydrofuranyl fentanyl	15
Tetrahydrothiofuranyl fentanyl	30
Thebacon	25
Thiafentanil	25
Thiofentanyl	25
Thiofuranyl fentanyl	30
THJ–2201 ([1-(5-fluoropentyl)-1H-indazol-3-yl](naphthalen-1-yl)methanone)	30
Tilidine	25
Trimeperidine	25
U–47700	30
UR–144 (1-pentyl-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone	25
Valeryl fentanyl	25
Zipeprol	30
Schedule II	
1-Phenylcyclohexylamine	15
1-Piperidinocyclohexanecarbonitrile	25
4-Anilino-N-phenethyl-4-piperidine (ANPP)	937,874
Alfentanil	5,000
Alphaprodine	25
Amobarbital	20,100
Bezitramide	25
Carfentanil	20
Cocaine	60,492
Codeine (for conversion)	942,452
Codeine (for sale)	19,262,516
d-Amphetamine (for conversion)	41,392,071
d-Amphetamine (for sale)	38,486,179
d-Methamphetamine (for conversion)	485,020
d-Methamphetamine (for sale)	47,000
d,l-Amphetamine	32,902,638
d,l-Methamphetamine	150
Dexmethylphenidate (for conversion)	5,374,683
Dexmethylphenidate (for sale)	6,200,000
Dextropropoxyphene	35
Dihydrocodeine	115,227
Dihydroetorphine	25
Diphenoxylate (for conversion)	14,100
Diphenoxylate (for sale)	770,800
Ecgonine	60,492
Ethylmorphine	30
Etorphine hydrochloride	32
Fentanyl	731,028
Glutethimide	25
Hydrocodone (for conversion)	1,250
Hydrocodone (for sale)	26,842,228
Hydromorphone	2,355,621
Isomethadone	30
l-Amphetamine	30
l-Methamphetamine	587,229
Levo-alphacetylmethadol (LAAM)	25
Levomethorphan	30
Levorphanol	20,000
Lisdexamfetamine	62,832,521
Meperidine	681,184
Meperidine Intermediate-A	30
Meperidine Intermediate-B	30
Meperidine Intermediate-C	30
Metazocine	15
Methadone (for sale)	25,619,700
Methadone Intermediate	27,673,600
Methylphenidate (for conversion)	19,975,468
Methylphenidate (for sale)	69,502,651
Metopon	25
Moramide-intermediate	25
Morphine (for conversion)	2,393,200
Morphine (for sale)	23,000,000
Nabilone	62,000
Norfentanyl	25

Basic class	Established 2027 quotas (g)
Noroxymorphone (for conversion)	24,756,979
Noroxymorphone (for sale)	2,500
Oliceridine	25,100
Opium (powder)	250,000
Opium (tincture)	530,837
Oripavine	45,721.950
Oxycodone (for conversion)	437,827
Oxycodone (for sale)	49,829,934
Oxymorphone (for conversion)	31,773,105
Oxymorphone (for sale)	464,270
Pentobarbital	55,216,002
Phenazocine	25
Phencyclidine	35
Phenmetrazine	25
Phenylacetone	100
Piminodine	25
Racemethorphan	5
Racemorphan	5
Remifentanil	6,152
Secobarbital	172,100
Sufentanil	4,000
Tapentadol	10,390,226
Thebaine	57,137,944
List I Chemicals	
Ephedrine (for conversion)	41,100
Ephedrine (for sale)	3,933,336
Phenylpropanolamine (for conversion)	15,500,000
Phenylpropanolamine (for sale)	7,990,000
Pseudoephedrine (for conversion)	1,000
Pseudoephedrine (for sale)	186,617,466

The Administrator further proposes that the APQ for all other schedule I and II controlled substances included in 21 CFR 1308.11 and 1308.12 remain at zero.

These proposed 2027 quotas reflect the quantities that DEA believes are necessary to meet the estimated medical, scientific, research, and industrial needs of the United States, lawful export requirements; and the establishment and maintenance of reserve stocks.

In accordance with 21 CFR 1303.13 and 1315.13, upon consideration of the relevant factors, the Administrator may adjust the 2027 APQ and AAN as needed.

Conclusion

After consideration of any comments or objections, or after a hearing, if one is held, the Administrator will issue and publish in the **Federal Register** a final order establishing the 2027 APQ for controlled substances in schedules I and II and establishing an AAN for the list I chemicals ephedrine, pseudoephedrine, and phenylpropanolamine, as directed by 21 CFR 1303.11(c) and 1315.11(f).

Signing Authority

This document of the Drug Enforcement Administration was signed on November 3, 2026, by DEA Administrator Terrance C. Cole. That document with the original signature and date is maintained by DEA. For administrative purposes only, and in compliance with requirements of the Office of the Federal Register, the undersigned DEA Federal Register Liaison Officer has been authorized to sign and submit the document in electronic format for publication, as an official document of DEA. This administrative process in no way alters the legal effect of this document upon publication in the **Federal Register**.

Heather Achbach,

Federal Register Liaison Officer, Drug Enforcement Administration.

[FR Doc. 2026–22843 Filed 11–9–26; 8:45 am]

BILLING CODE P

NUCLEAR REGULATORY COMMISSION

[Docket Nos. 50–616 and 50–617; NRC–2026–0265]

SMR, LLC; Palisades SMR, LLC; Pioneer Units 1 and 2; Receipt of Construction Permit Application

AGENCY: Nuclear Regulatory Commission.

ACTION: Notice; receipt.

SUMMARY: The U.S. Nuclear Regulatory Commission (NRC) is providing public notice of receipt and availability each week, for four consecutive weeks, beginning November 10, 2026, of the second part of a phased construction permit application, from SMR, LLC, on behalf of Palisades SMR, LLC, a wholly-owned subsidiary of Holtec International, for a dual-unit SMR–300 plant located at the Palisades Energy Center (PEC) in Covert, Michigan. The units are individually named Pioneer Unit 1 and Pioneer Unit 2. This is the first of four consecutive weekly notifications. The application for the construction permits was received on September 30, 2026.

DATES: November 10, 2026.